Key result
Genome editing methods present promising experimental therapies for correcting mutations in Alzheimer's disease, though significant challenges remain before clinical implementation.
This review summarizes current achievements and challenges in using genome editing for experimental therapy of Alzheimer's disease.
Answers are grounded in this paper and cite their sources.
Genome editing for Alzheimer’s mutations remains experimental; leaves open clinical translation pending optimized delivery and safety data.
Abstract—Here, we review the current achievements in the use of genome editing methods for experimental therapy of neurodegenerative diseases, primarily Alzheimer’s disease. The main approaches used for genome editing and editing systems as well as their advantages and disadvantages are considered. Specific examples of the use of genome editing to correct mutations in genes associated with Alzheimer’s disease are presented. The existing problems that need to be solved for the introduction of genome editing in the practice of treating neurodegenerative diseases are analyzed.
No takes yet. Share an insight, caveat, or question.
M. Yu. Stepanichev (2021) conducted a review in Alzheimer's disease. Genome editing was evaluated. Genome editing methods present promising experimental therapies for correcting mutations in Alzheimer's disease, though significant challenges remain before clinical implementation.
Synapse has enriched 10 related papers. Consider them for comparative context: